KPMG New England Life Sciences Center

60 South Street, Two Financial Center, Boston, MA




Healthcare and life sciences M&A outlook: Bullish signals ahead

[Boston Business Journal] With both positive momentum and the competitive stakes so high, companies with the most knowledge, the greatest experience targeting innovative assets — and those that employ rapid and thorough due diligence — can prevail in this deal market.

Read the article


Latest feature from our Life Sciences Center

2022 HCLS investment outlook roundtable

For life sciences, we saw an average of about 460 deals on a quarterly basis, which was up from 2020, at about 405.

We look at life sciences, from a biopharma, diagnostics, biopharma and lab services and medical device, and in healthcare, it's the whole continuum of care.

Inflationary and geopolitical perspectives.

The life science industry broadly has been extremely active in 2020 and 2021.

We expect the healthcare IT growth trend to continue.

An area to more closely gauge in 2022.

Convergence of payers and providers.

2022 HCLS investment outlook roundtable

For life sciences, we saw an average of about 460 deals on a quarterly basis, which was up from 2020, at about 405.

We look at life sciences, from a biopharma, diagnostics, biopharma and lab services and medical device, and in healthcare, it's the whole continuum of care.

Inflationary and geopolitical perspectives.

The life science industry broadly has been extremely active in 2020 and 2021.

We expect the healthcare IT growth trend to continue.

An area to more closely gauge in 2022.

Convergence of payers and providers.

2022 HCLS investment outlook roundtable

For life sciences, we saw an average of about 460 deals on a quarterly basis, which was up from 2020, at about 405.

We look at life sciences, from a biopharma, diagnostics, biopharma and lab services and medical device, and in healthcare, it's the whole continuum of care.

Inflationary and geopolitical perspectives.

The life science industry broadly has been extremely active in 2020 and 2021.

We expect the healthcare IT growth trend to continue.

An area to more closely gauge in 2022.

Convergence of payers and providers.

2022 HCLS investment outlook roundtable

For life sciences, we saw an average of about 460 deals on a quarterly basis, which was up from 2020, at about 405.

We look at life sciences, from a biopharma, diagnostics, biopharma and lab services and medical device, and in healthcare, it's the whole continuum of care.

Inflationary and geopolitical perspectives.

The life science industry broadly has been extremely active in 2020 and 2021.

We expect the healthcare IT growth trend to continue.

An area to more closely gauge in 2022.

Convergence of payers and providers.

2022 HCLS investment outlook roundtable

For life sciences, we saw an average of about 460 deals on a quarterly basis, which was up from 2020, at about 405.

We look at life sciences, from a biopharma, diagnostics, biopharma and lab services and medical device, and in healthcare, it's the whole continuum of care.

Inflationary and geopolitical perspectives.

The life science industry broadly has been extremely active in 2020 and 2021.

We expect the healthcare IT growth trend to continue.

An area to more closely gauge in 2022.

Convergence of payers and providers.

KPMG and MassBio on aligning financial management systems with biotech lifecycles: From pre-commercial to high-growth

2022 HCLS investment outlook roundtable

For life sciences, we saw an average of about 460 deals on a quarterly basis, which was up from 2020, at about 405.

We look at life sciences, from a biopharma, diagnostics, biopharma and lab services and medical device, and in healthcare, it's the whole continuum of care.

Inflationary and geopolitical perspectives.

The life science industry broadly has been extremely active in 2020 and 2021.

We expect the healthcare IT growth trend to continue.

An area to more closely gauge in 2022.

Convergence of payers and providers.


Video Series: Disruption in Life Sciences (ft. Mary Rollman, KPMG)

2022 HCLS investment outlook roundtable

For life sciences, we saw an average of about 460 deals on a quarterly basis, which was up from 2020, at about 405.

We look at life sciences, from a biopharma, diagnostics, biopharma and lab services and medical device, and in healthcare, it's the whole continuum of care.

Inflationary and geopolitical perspectives.

The life science industry broadly has been extremely active in 2020 and 2021.

We expect the healthcare IT growth trend to continue.

An area to more closely gauge in 2022.

Convergence of payers and providers.




Visit our national Healthcare & Life Sciences Institute

An open forum for business leaders across the industry to share perspectives, gain insight, develop approaches to help balance risk and improve performance.

Go there now




Get to know us

Led by a nationally-recognized team of life science experts, the KPMG New England Life Sciences Center helps clients address their most complex challenges. From strategy to execution and from early-stage to IPO and beyond, our team collaboratively works with senior executives to create a lasting, meaningful impact across three areas of focus:
Growth, Profit, and Protection

Regional Industry Leaders

David Frey

David Frey

Principal, Advisory, Life Sciences Leader, New England & Upstate New York, KPMG LLP

Kristin C. Pothier

Kristin C. Pothier

Global and National Leader, HCLS Strategy, KPMG LLP

+1 617 549 2779
Jeff Stoll, PhD

Jeff Stoll, PhD

Principal, National Strategy Life Sciences Leader, KPMG US

+1 617-988-1000
Janet Lehman

Janet Lehman

Partner, Audit, U.S. Venture Capital Life Sciences Leader, KPMG US

Alasdair Milton, PhD

Alasdair Milton, PhD

Managing Director, Healthcare and Life Sciences Strategy, KPMG US

+1 617-988-5419
Mary J. Rollman

Mary J. Rollman

Principal, Advisor/Supply Chain Strategy and Life Sciences Lead, KPMG US

+1 312-618-9863
Rajesh Misra

Rajesh Misra

Principal, Life Sciences Advisory, KPMG US

+1-617-988-1184



Let's connect




[Video] David Frey from KPMG and Mike Kennealy, Mass. Secretary of Housing and Economic Development, connect to discuss how the life sciences sector expanding to outlying communities is creating additional regional clusters of biotech innovation in the area.



Life Science jobs at KPMG

Find your fit with our team in New England and Upstate New York!

Search jobs


Life Sciences Thought Leadership